Zimbabwe has rejected a significant American health deal valued at 367 million US dollars (272 million pounds) spanning five years because of Washington's demand for sensitive information.
This move was revealed after a internal memorandum from December was leaked, which showed Head of State Emmerson Mnangagwa believed the deal was "unbalanced".
An official representative has since explained that the US was requesting genetic material for scientific study and commercial purposes but was not willing to guarantee the benefits from any future vaccines.
"We are forced to start the difficult and regrettable task of ending our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the US had donated over $1.9bn as health assistance to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has appealed for further negotiations to secure a deal acceptable to all parties so the nation's vital HIV treatment initiative can be sustained.
Wider Context
Zimbabwe's decision comes after a similar case in Kenya, where a high court blocked a similar health funding agreement following legal challenges were filed about the security of Kenyans' health data.
After resuming office last year, US President Donald Trump has drastically cut overseas assistance and closed the key foreign aid agency.
USAID had administered aid for the American government, but Trump claimed its spending was "wasteful" and his government was pursuing government-to-government deals to enhance openness and responsibility.
As per statements, 16 nations in Africa have to date agreed to similar health pacts, constituting over $18.3bn in committed funds.
Specifics of the Declined Agreement
The funds for Zimbabwe would have funded "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this cooperation would have delivered immense advantages for the people of Zimbabwe, particularly the 1.2 million men, women and children currently receiving HIV treatment through US-supported initiatives," Tremont added.
However, government spokesperson Nick Mangwana maintained the proposed deal was "asymmetrical".
"Our nation was requested to share its biological resources and data over an extended period, without any corresponding assurance of benefiting from any medical innovations – such as vaccines, diagnostics, or treatments – that could be developed from that provided information," Mangwana explained.
"In essence, our country would provide the raw materials for medical research with no assurance that the final treatments would be accessible to our citizens should a new pandemic arise."
Sovereignty and International Frameworks
He also said that the American exit from the global health body and its pursuit of one-on-one deals were undermining structures already set up via the international health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing scheme created to manage potential pandemics.
"This mechanism is designed to ensure that when a nation provides its samples, the benefits – such as vaccines and treatments – are distributed fairly, not monopolised exclusively by those with the funds to develop them."
The government's concerns regarding the US deal "must not be interpreted as anti-American sentiment," Mangwana stressed.
"We encourage further dialogue with our American counterparts on how subsequent collaboration could be structured in a way that honours the independence and interests of each country."
Medical Community Response
Medical experts said it acknowledged the official position, but recommended that negotiations should continue given that much of the country's Aids initiatives relied on international support.
"If technical issues exist, including those relating to information security or agreement terms, these can often be addressed via technical clarification and mutually agreed protections," the group commented.
The halted deal emphasises the continuing challenges between accepting crucial foreign assistance and protecting local interests in an ever more data-driven world.